An old drug in a new era: digitoxin in the spotlight after DIGIT-HF
Bibliographic record
Abstract
For more than two centuries, cardiac (digitalis) glycosides have been used in the treatment of heart failure (HF), but robust randomized evidence has been limited. The landmark DIG trial,1 published in 1997, showed that digoxin had no effect on all-cause mortality (the primary outcome) but reduced hospitalizations for worsening HF (a secondary outcome), with benefits most evident at low serum concentrations. Of note, side effects and overdose risk with digoxin are well recognized and relatively frequent, particularly in elderly patients.1 Digitoxin, a related digitalis glycoside with high lipophilicity and mainly hepatic route of elimination, has long been viewed as a potential alternative, yet had never been rigorously tested in a contemporary randomized trial. Presented as a Hot Line trial at the European Society of Cardiology Congress 2025 in Madrid, the DIGIT-HF trial2 sought to fill this knowledge gap. In a Phase 4, double-blind, placebo-controlled study, 1240 patients with symptomatic HF and reduced left ventricular ejection fraction (LVEF) were randomized, of whom 1212 were included in the modified intention-to-treat analysis.2 Eligible patients had either an LVEF ≤ 40% and a New York Heart Association (NYHA) Class III-IV, or a LVEF ≤ 30% and a NYHA Class II. Background medications were consistent with guideline-directed medical therapy: over 90% received beta-blockers, 40% were on angiotensin receptor-neprilysin inhibitors, 76% on mineralocorticoid receptor antagonists, and nearly 20% on sodium-glucose cotransporter 2 inhibitors; implantable defibrillators and cardiac resynchronization therapy were reported in about 64% and 25%, respectively. Over a median follow-up of 36 months, the primary outcome of all-cause death or first hospitalization for worsening HF occurred in 39.5% of patients assigned to digitoxin and 44.1% of those receiving placebo [hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.69–0.98; P = 0.03]. All-cause mortality (HR 0.86; 95% CI 0.69–1.07) and first hospitalization for worsening HF (HR 0.85; 95% CI 0.69–1.05) were each numerically lower with digitoxin. Serious adverse events occurred slightly more often with digitoxin (4.7% vs. 2.8%). DIGIT-HF provides the first evidence from a randomized trial for a prognostic benefit of a cardiac glycoside on top of comprehensive guideline-directed medical and device therapy.2-5 Although the trial was underpowered relative to its original design, digitoxin appeared generally well tolerated with a simple titration protocol and may be particularly useful in patients with atrial fibrillation, higher heart rates, low blood pressure, or impaired renal function. DIGIT-HF marks a potential renaissance for cardiac glycosides in HF and is likely to inform future discussions on guideline recommendations and disease management. The data underlying this article were taken from the quoted references.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.005 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".